

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中基長壽科學

ZHONG JI LONGEVITY SCIENCE

Zhong Ji Longevity Science Group Limited

中基長壽科學集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

**INTERIM RESULTS ANNOUNCEMENT
FOR THE SIX MONTHS ENDED 30 JUNE 2026**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Zhong Ji Longevity Science Group Limited (the “**Company**”) is pleased to announce the unaudited condensed consolidated interim results of the Company and its subsidiaries (collectively, the “**Group**”) for the six months ended 30 June 2026 (“**HY2026**”) together with the comparative figures for the corresponding period in 2025 (“**HY2025**”). The interim results have been reviewed by the audit committee of the Company (the “**Audit Committee**”).

FINANCIAL HIGHLIGHTS

- For HY2026, the Group’s revenue increased by 49.0% to HK\$71.5 million (HY2025: HK\$48.0 million).
- For HY2026, the Group’s gross profit increased by 2.5% to HK\$16.4 million (HY2025: HK\$16.0 million).
- For HY2026, the Group recorded a loss before tax of approximately HK\$4.9 million (HY2025: loss before tax of approximately HK\$11.5 million).
- As at 30 June 2026, the Group’s net assets increased by 2.9% to HK\$437.5 million (31 December 2025: HK\$425.0 million).
- For HY2026, the Board does not recommend the payment of an interim dividend for the year (HY2025: Nil).

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS
FOR THE SIX MONTHS ENDED 30 JUNE 2026

		Six months ended 30 June	
		2026	2025
		HK\$'000	HK\$'000
	<i>Notes</i>	(Unaudited)	(Unaudited)
Revenue	4	71,526	47,973
Cost of sales and services rendered		<u>(55,142)</u>	<u>(31,945)</u>
Gross profit		16,384	16,028
Other income and gains or losses	5	1,518	75
Selling and distribution expenses		(3,865)	(1,520)
Administrative expenses		(18,736)	(25,452)
Finance costs	6	<u>(248)</u>	<u>(663)</u>
LOSS BEFORE TAX	7	(4,947)	(11,532)
Income tax expense	8	<u>(1,423)</u>	<u>(1,390)</u>
LOSS FOR THE PERIOD		<u><u>(6,370)</u></u>	<u><u>(12,922)</u></u>
Attributable to:			
Owners of the Company		(6,510)	(12,571)
Non-controlling interests		<u>140</u>	<u>(351)</u>
		<u><u>(6,370)</u></u>	<u><u>(12,922)</u></u>
LOSS PER SHARE ATTRIBUTABLE TO OWNERS OF THE COMPANY	9		
Basic and diluted		<u><u>(HK1.02 cents)</u></u>	<u><u>(HK2.29 cents)</u></u>

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE SIX MONTHS ENDED 30 JUNE 2026

	Six months ended 30 June	
	2026	2025
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
LOSS FOR THE PERIOD	<u>(6,370)</u>	<u>(12,922)</u>
OTHER COMPREHENSIVE INCOME		
<i>Item that may be reclassified to profit or loss in subsequent periods:</i>		
Exchange differences on translation of foreign operations	<u>18,838</u>	<u>13,561</u>
	18,838	13,561
<i>Item that may not be reclassified to profit or loss in subsequent periods:</i>		
Changes in fair value of equity investments designated at fair value through other comprehensive income	<u>—</u>	<u>120</u>
	—	120
OTHER COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	<u>18,838</u>	<u>13,681</u>
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	<u>12,468</u>	<u>759</u>
Attributable to:		
Owners of the Company	<u>11,672</u>	<u>711</u>
Non-controlling interests	<u>796</u>	<u>48</u>
	<u>12,468</u>	<u>759</u>

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AT 30 JUNE 2026

		30 June 2026 HK\$'000 (Unaudited)	31 December 2025 HK\$'000 (Audited)
	<i>Notes</i>		
NON-CURRENT ASSETS			
Plant and equipment	<i>11</i>	408	526
Investment properties		24,017	23,533
Right-of-use assets	<i>12</i>	3,246	5,166
Interests in joint ventures		—	—
Financial assets at fair value through other comprehensive income	<i>13</i>	—	—
Total non-current assets		27,671	29,225
CURRENT ASSETS			
Inventories		582	391
Loan and interest receivables	<i>14</i>	186,401	169,324
Trade receivables	<i>15</i>	61,061	25,169
Deposits, prepayments and other receivables	<i>16</i>	228,122	216,753
Tax recoverable		3,844	3,695
Amounts due from related companies	<i>20</i>	30,000	31,053
Cash and cash equivalents		13,400	24,299
Total current assets		523,410	470,684
CURRENT LIABILITIES			
Trade payables	<i>17</i>	55,446	24,358
Other payables and accruals	<i>18</i>	15,195	11,178
Bank and other borrowings	<i>19</i>	2,238	—
Lease liabilities		1,467	2,896
Amounts due to related companies	<i>20</i>	10,483	9,422
Contract liabilities		1,640	1,604
Tax payable		24,330	21,913
Total current liabilities		110,799	71,371

		30 June 2026 HK\$'000 (Unaudited)	31 December 2025 HK\$'000 (Audited)
	<i>Note</i>		
NET CURRENT ASSETS		412,611	399,313
TOTAL ASSETS LESS CURRENT LIABILITIES		440,282	428,538
NON-CURRENT LIABILITIES			
Deferred tax liabilities		901	873
Lease liabilities		1,919	2,671
Total non-current liabilities		2,820	3,544
NET ASSETS		437,462	424,994
EQUITY			
Share capital	<i>21</i>	6,366	6,366
Reserves		402,865	391,193
Equity attributable to owners of the Company		409,231	397,559
Non-controlling interests		28,231	27,435
Total equity		437,462	424,994

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Six months ended 30 June 2026

1. GENERAL INFORMATION

Zhong Ji Longevity Science Group Limited (the “**Company**”) is a limited liability company incorporated in Bermuda and its shares are listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). As at 30 June 2026, the directors of the Company consider the ultimate controlling shareholders of the Company is Mr. Yan Li, who is also the chairman of the Company. The registered address of the Company is located at Victoria Place, 5th Floor, 31 Victoria Street, Hamilton HM 10, Bermuda, and the principal place of business of the Company is located at Room 606, 6/F., Phase I of Austin Tower, Nos. 152–152A Austin Road and Nos. 22–26A Austin Avenue, Kowloon, Hong Kong.

During the period, the principal activities of the Company and its subsidiaries (the “**Group**”) are as follows:

- Longevity science business
- Money lending & Financial advisory
- Securities and other investments
- Property investment

The condensed consolidated financial statements are presented in Hong Kong dollars (“**HK\$**”), which is also the functional currency of the Company.

2. BASIS OF PREPARATION

The condensed consolidated financial statements have been prepared in accordance with Hong Kong Accounting Standard 34 (“**HKAS 34**”) “Interim Financial Reporting” issued by the Hong Kong Institute of Certified Public Accountants (the “**HKICPA**”) as well as the applicable disclosures requirements of the Rules Governing the Listing of Securities on the Stock Exchange.

3. PRINCIPAL ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis except for investment properties and financial assets at fair value through other comprehensive income that are measured at fair values, as appropriate.

Other than change in accounting policies resulting from application of amendments to HKFRS Accounting Standards, the accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended 30 June 2026 are the same as those presented in the Group’s annual financial statements for the year ended 31 December 2025.

3. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

Application of amendments to HKFRS Accounting Standards

In the current interim period, the Group has applied the following amendments to HKFRS Accounting Standards issued by the HKICPA, for the first time, which are mandatory effective for the Group's annual period beginning on 1 January 2026 for the preparation of the Group's condensed consolidated financial statements:

Amendments to HKFRS 9 and HKFRS 7	Amendments to the Classification and Measurement of Financial Instruments
Annual Improvements to HKFRS Accounting Standards — Volume 11	Amendments to HKFRS 1, HKFRS 7, HKFRS 9, HKFRS 10 and HKAS 7
Amendments to HKFRS 9 and HKFRS 7	Contracts Referencing Nature-dependent Electricity

The application of the amendments to HKFRS Accounting Standards in the current interim period has had no material impact on the Group's financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

4. REVENUE AND SEGMENT INFORMATION

Disaggregation of revenue from contracts with customers

	Six months ended 30 June	
	2026	2025
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Revenue from contracts with customers within the scope of HKFRS 15		
Sales of health and medical products	60,378	32,555
Provision of diagnostic and medical test services	287	1,698
	<u>60,665</u>	<u>34,253</u>
Revenue from other sources		
Loan interest income	10,861	13,720
	<u>10,861</u>	<u>13,720</u>
Total revenue recognised during the period	<u>71,526</u>	<u>47,973</u>
Timing of revenue recognition within the scope of HKFRS 15		
A point in time	<u>60,665</u>	<u>34,253</u>

The executive directors of the Company, being the chief operating decision makers ("CODM"), review the Group's internal reporting in order to assess performance and allocate resources. Information reported to the CODM, for the purpose of resources allocation and performance assessment, focuses on the types of goods or services delivered or provided.

The Group's reportable segments under HKFRS 8 *Operating Segments* are as follows:

- (a) Longevity science business: provision of diagnostic consultation, health and medical testing and checking, distribution of cancer prevention & immunity healthcare supplements and the sales and distribution of longevity wine;
- (b) Money lending and financial advisory business: provision of loan financing for earning interest income and provision of financial advisory and management services rendering various loans fees;
- (c) Securities and other investments: holding of equity investments and investment in short to long-term financial assets for dividend income; and
- (d) Property investment: investment in properties for rental income and/or for potential capital appreciation.

No operating segments have been aggregated in arriving the reportable segments of the Group.

Management monitors the results of the Group's operating segments separately for the purpose of making decisions about resources allocation and performance assessment. Segment performance is evaluated based on reportable segment profit/(loss), which is a measure of adjusted profit /(loss) before tax. The adjusted profit/(loss) before tax is measured consistently with the Group's profit/(loss) before tax except that bank interest income, finance costs, and corporate and other unallocated income or expenses, net and corporate income and expenses are excluded from such measurement.

Segment assets exclude tax recoverable and corporate and other unallocated corporate assets as these assets are managed on a group basis.

Segment liabilities exclude tax payable, deferred tax liabilities and other unallocated corporate liabilities as these liabilities are managed on a group basis.

	Longevity science business HK\$'000	Money lending and financial advisory business HK\$'000	Securities and other investments HK\$'000	Property investment HK\$'000	Total HK\$'000
Six months ended 30 June 2026 (unaudited)					
Revenue from external customers	60,665	10,861	–	–	71,526
Segment (loss)/profit	(6,395)	9,479	(8)	–	3,076
As at 30 June 2026 (unaudited)					
Segment assets	79,583	373,876	3,250	24,320	481,029
Segment liabilities	60,474	14,273	–	–	74,747
Six months ended 30 June 2025 (unaudited)					
Revenue from external customers	34,253	13,720	–	–	47,973
Segment (loss)/profit	(10,945)	12,306	(20)	–	1,341
As at 31 December 2025 (audited)					
Segment assets	53,202	345,831	3,999	23,932	426,964
Segment liabilities	26,340	15,571	–	–	41,911

Reconciliations of segment results and segment assets and segment liabilities:

	Six months ended 30 June	
	2026	2025
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Segment results		
Total segment results of reportable segments	3,076	1,341
Bank interest income	–	123
Finance costs	(223)	(663)
Corporate and other unallocated expenses, net	(7,800)	(12,333)
Loss before tax	(4,947)	(11,532)
	30 June	31 December
	2026	2025
	HK\$'000	HK\$'000
	(Unaudited)	(Audited)
Segment assets		
Total segment assets of reportable segments	481,029	426,964
Tax recoverable	3,844	3,695
Corporate and other unallocated assets	66,208	69,250
Total assets	551,081	499,909
Segment liabilities		
Total segment liabilities of reportable segments	74,747	41,911
Tax payable	24,330	21,913
Deferred tax liabilities	901	873
Corporate and other unallocated liabilities	13,641	10,218
Total liabilities	113,619	74,915

Geographical information

Revenue from external customers

	Six months ended 30 June 2026 <i>HK\$'000</i> (Unaudited)	Six months ended 30 June 2025 <i>HK\$'000</i> (Unaudited)
Geographical markets		
Hong Kong	60,665	35,190
Mainland China of the People's Republic of China ("PRC")	10,861	12,783
	<u>71,526</u>	<u>47,973</u>

5. OTHER INCOME AND OTHER GAINS OR LOSSES

	Six months ended 30 June 2026 <i>HK\$'000</i> (Unaudited)	2025 <i>HK\$'000</i> (Unaudited)
Bank interest income	–	123
Exchange loss, net	(2)	(63)
Gain on early termination of right-of-use assets and lease liabilities	–	12
Interest income from amounts due from related companies	1,500	–
Others	20	3
	<u>1,518</u>	<u>75</u>

6. FINANCE COSTS

	Six months ended 30 June	
	2026	2025
	<i>HK\$'000</i>	<i>HK\$'000</i>
	(Unaudited)	(Unaudited)
Interest on bank and other borrowings	25	372
Interest on lease liabilities	223	291
	<u>248</u>	<u>663</u>

7. LOSS BEFORE TAX

The Group's loss before tax is arrived at after charging the following items:

	Six months ended 30 June	
	2026	2025
	<i>HK\$'000</i>	<i>HK\$'000</i>
	(Unaudited)	(Unaudited)
Depreciation of plant and equipment	134	179
Depreciation of right-of-use assets	1,920	3,301
Staff costs (including directors' emoluments)	10,562	10,429
	<u>10,562</u>	<u>10,429</u>

8. INCOME TAX EXPENSE

	Six months ended 30 June	
	2026	2025
	<i>HK\$'000</i>	<i>HK\$'000</i>
	(Unaudited)	(Unaudited)
Current tax — PRC Enterprise Income Tax (“EIT”)		
— Charge for the period	1,423	1,390
	<u>1,423</u>	<u>1,390</u>

Under the two-tiered profits tax rates regime in Hong Kong, the first HK\$2,000,000 of assessable profits of the qualifying corporation in the Group are taxed at 8.25%, and assessable profits above HK\$2 million are taxed at 16.5%. The assessable profits of corporations in Hong Kong not qualifying for the two-tiered profits tax rates regime will continue to be taxed at a flat rate of 16.5%.

The two-tiered profits tax rates regime is applicable to the Group for both periods.

Under the Law of the EIT and Implementation Regulation of the EIT Law, the tax rate of the PRC subsidiaries is 25% for both periods.

9. LOSS PER SHARE

The calculations of the basic and diluted loss per share attributable to owners of the Company are based on the following data:

	Six months ended 30 June	
	2026	2025
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Loss:		
Loss for the period attributable to owners of the Company, used in the basic and diluted loss per share calculations	<u>(6,510)</u>	<u>(12,571)</u>
	Number of shares	
	Six months ended 30 June	
	2026	2025
	'000	'000
	(Unaudited)	(Unaudited)
Shares:		
Weighted average number of ordinary shares in issue during the period used in the basic and diluted loss per share calculation	<u>636,653</u>	<u>549,033</u>

The computation of diluted loss per share for the six months ended 30 June 2026 and 2025 does not assume the exercise of the Company's share options because the exercise price of those share options was higher than the average market price for both periods.

10. DIVIDEND

The directors do not recommend the payment of any dividend for the six months ended 30 June 2026 (30 June 2025: nil).

11. MOVEMENTS IN PLANT AND EQUIPMENT

During the six months ended 30 June 2026, the Group had no addition nor disposal of plant and equipment (30 June 2025: additions of furniture & fixture of approximately HK\$10,000 with no disposal of plant and equipment).

12. MOVEMENTS IN RIGHT-OF-USE ASSETS

During the six months ended 30 June 2026, the Group had no addition of lease contracts for various items of leasehold land and buildings (30 June 2025: additions of approximately HK\$4,731,000).

13. FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME

	30 June 2026 HK\$'000 (Unaudited)	31 December 2025 HK\$'000 (Audited)
Listed equity investments, at fair value	<u>—</u>	<u>—</u>

The above equity investments are investments in companies listed on the Stock Exchange and were irrevocably designated at fair value through other comprehensive income as the Group considers these investments are not held for trading, instead, they are held for long-term strategic purposes.

The fair value of the listed equity investments is based on their current quoted prices in active markets, and therefore classified under level 1 of the fair value hierarchy.

During the year ended 31 December 2025, the Group sold all of its equity investments at an aggregate consideration of HK\$2,280,000 as these investments were no longer coincided with the Group's investment objective of the Group. A cumulative gain on disposal of equity investments of FVTOCI of HK\$87,977,000 recognised in other comprehensive income was transferred to accumulated losses during the year ended 31 December 2025.

14. LOAN AND INTEREST RECEIVABLES

	30 June 2026 HK\$'000 (Unaudited)	31 December 2025 HK\$'000 (Audited)
Loan and interest receivables		
— corporate loans	621,746	604,936
Loan and interest receivables		
— personal loans	<u>239,815</u>	<u>239,548</u>
	861,561	844,484
Less: allowance for credit losses		
— Stage 2	(51,010)	(51,010)
— Stage 3	<u>(624,150)</u>	<u>(624,150)</u>
	<u>(675,160)</u>	<u>(675,160)</u>
	<u>186,401</u>	<u>169,324</u>

The term of loans entered with its customers are on credit. The credit period is generally within four years, extension can be made after monitoring assessment and further creditworthiness analysis on the debtors reviewed by senior management. The loan receivables carried at fixed interest rate ranging from 6% to 18% (31 December 2025: 6% to 18%) per annum. The Group seeks to maintain strict control over its outstanding receivables, and thus overdue balances are reviewed regularly by senior management. The Group held collateral or other credit enhancements over its certain of its loan and interest receivable balances.

The Group's loans and interest receivable, which arise from the money lending business under corporate and personal borrowers loan business model of providing corporate and personal loans in the Mainland China of the PRC and in Hong Kong and the carrying amounts approximate their fair values.

Except for loan and interest receivables of HK\$664,859,000 (31 December 2025: HK\$659,519,000) which are unsecured, loan and interest receivables are secured by collateral provided by customers, bearing interest ranging from 6% to 15% (31 December 2025: 6% to 15%) per annum and are repayable within one year.

Included in the Group's loan and interest receivables are amounts due from the Group's joint ventures with net carrying amount of HK\$32,092,000 (31 December 2025: HK\$28,442,000), which are unsecured, bearing interest at 12% (31 December 2025: 12%) per annum and are repayable within one year.

The following is an aged analysis of the loan and interest receivables presented as at the end of the reporting period, based on commencement of loan agreements entered into and the date of interest income accrued, and net of allowance for credit losses:

	30 June 2026 HK\$'000 (Unaudited)	31 December 2025 HK\$'000 (Audited)
Within 30 days	997	958
31–90 days	1,994	2,874
91–180 days	2,990	2,874
181–365 days	5,981	2,874
Over 365 days	174,439	159,744
	186,401	169,324

15. TRADE RECEIVABLES

	30 June 2026 HK\$'000 (Unaudited)	31 December 2025 HK\$'000 (Audited)
Trade receivables	61,068	25,176
Less: allowance for credit losses	(7)	(7)
	61,061	25,169

The Group's trading terms with its customers are mainly on credit. The credit period is generally 30 to 90 days for its trade receivables. Regarding the longevity science business, the Group generally requests for deposits in advance from customers. The Group seeks to maintain strict control over its outstanding receivables to minimise credit risk and overdue balances are reviewed regularly by senior management. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. Trade receivables are non-interest-bearing.

The following is an aged analysis of trade receivables presented based on the invoice date, net of allowance for credit losses:

	30 June 2026 HK\$'000 (Unaudited)	31 December 2025 HK\$'000 (Audited)
Current to 30 days	30,344	24,512
31–90 days	30,034	–
91–180 days	–	–
181–365 days	–	–
Over 365 days	683	657
	<u>61,061</u>	<u>25,169</u>

16. DEPOSITS, PREPAYMENTS AND OTHER RECEIVABLES

	30 June 2026 HK\$'000 (Unaudited)	31 December 2025 HK\$'000 (Audited)
Prepayments	2,688	2,928
Deposits	2,204	2,238
Other receivables — personal loans via strategic partners by 100% contribution	149,122	140,926
Other receivables — personal loans via strategic partners by 10% contribution	45,474	43,708
Other receivables — others (<i>note</i>)	98,552	96,871
Less: allowance for credit losses		
— Stage 1	(1,734)	(1,734)
— Stage 2	(46,989)	(46,989)
— Stage 3	(21,195)	(21,195)
	<u>228,122</u>	<u>216,753</u>

Note: As at 30 June 2026, other receivables — others included the refundable receivables of HK\$19,738,000 (31 December 2025: HK\$19,738,000) for consultancy fee.

17. TRADE PAYABLES

The following is an aged analysis of trade payables based on invoice date:

	30 June 2026 HK\$'000 (Unaudited)	31 December 2025 HK\$'000 (Audited)
Current to 30 days	55,446	24,246
31–60 days	–	–
61–90 days	–	–
Over 90 days	–	112
	<u>55,446</u>	<u>24,358</u>

18. OTHER PAYABLES AND ACCRUALS

	30 June 2026 HK\$'000 (Unaudited)	31 December 2025 HK\$'000 (Audited)
Other payables	1,017	797
Accruals	14,178	10,381
	<u>15,195</u>	<u>11,178</u>

19. BANK AND OTHER BORROWINGS

As at 30 June 2026, the Group obtained PRC bank loan of approximately HK\$2,238,000 (31 December 2025: nil), which is unsecured, bearing interest at 3.0% per annum and payable within one year.

20. AMOUNTS DUE FROM/(TO) RELATED COMPANIES

For the six months ended 30 June 2026, the amount due from Zhong Ji 1 International Medical Group (Hong Kong) Limited of HK\$30,000,000 (31 December 2025: HK\$30,000,000) is a revolving credits facility being unsecured, bearing interest at 10% per annum and repayable on demand (31 December 2025: same).

For the six months ended 30 June 2026, except for the amount due from related company mentioned above, the amounts due from/(to) related companies are unsecured, interest-free and repayable on demand (31 December 2025: same).

Mr. Yan Li is a director and beneficial owner of those related companies of the Company.

21. SHARE CAPITAL

	30 June 2026 <i>HK\$'000</i> (Unaudited)	31 December 2025 <i>HK\$'000</i> (Audited)
Authorised:		
40,000,000,000 ordinary shares of HK\$0.01 each	<u>400,000</u>	<u>400,000</u>
	Number of shares in issue '000	Share capital <i>HK\$'000</i>
Issued and fully paid:		
At 1 January 2025 (audited)	546,530	5,465
Issue of new shares (<i>Note (a)</i>)	<u>90,124</u>	<u>901</u>
At 31 December 2025 (audited), 1 January 2026 (audited) and 30 June 2026 (unaudited)	<u>636,654</u>	<u>6,366</u>

Note:

- (a) On 25 June 2025, a total of 90,124,751 new shares were issued through shares subscription at the subscription price of HK\$0.34 per share.

22. CONTINGENT LIABILITIES

The Group did not have any significant contingent liabilities as at 30 June 2026 (31 December 2025: same).

23. CAPITAL COMMITMENT

The Group did not have any capital commitment as at 30 June 2026 (31 December 2025: same).

24. RELATED PARTY TRANSACTIONS

In addition to the transactions or balances detailed elsewhere in these financial statements, the Group had the following material transactions and balances with related parties during the period:

- (a) For the six months ended 30 June 2026, loan interest income of HK\$1,019,000 (six months ended 30 June 2025: HK\$960,000) and HK\$513,000 (six months ended 30 June 2025: HK\$483,000) were receivable from Chongqing Juquan Business Information Consulting Co., Limited (“Chongqing Juquan”) and Wuxi Juquan Outsourcing Service Co., Limited (“Wuxi Juquan”) respectively, the joint ventures of the Group.
- (b) For the six months ended 30 June 2026, loan interest income of HK\$1,500,000 (six months ended 30 June 2025: HK\$1,500,000) was receivable from Zhong Ji 1 International Medical Group (Hong Kong) Limited, being a related company as the chairman and executive director, Mr. Yan Li held 90.76% beneficiary interest as at 30 June 2026. These related party transactions constitute connected transactions as defined in Chapter 14A of the Listing Rules.
- (c) Outstanding balances with related parties:
 - (i) The Group had HK\$30,000,000 (31 December 2025: HK\$30,000,000) of outstanding balance due from Zhong Ji 1 International Medical Group (Hong Kong) Limited, being a related company as the chairman and executive director, Mr. Yan Li held 90.76% beneficiary interest as at 30 June 2026.
 - (ii) The Group had approximately HK\$1,053,000 (30 June 2026: nil) executive outstanding balance due from Shenzhen Zhongji Hirain Investment Limited as at 31 December 2025, being a related company as the chairman and executive director, Mr. Yan Li held 99% interest as at 30 June 2026.
 - (iii) The Group had approximately HK\$802,000 (31 December 2025: HK\$771,000) of outstanding balance due to Chongqing Juguan as at 30 June 2026. In addition, the Group had HK\$3,086,000 (31 December 2025: HK\$2,966,000) outstanding balance due to Wuxi Juguan as at 30 June 2026. Both were joint ventures with 51% held by a wholly owned subsidiary of the Group in the PRC.
 - (iv) The Group had approximately HK\$6,595,000 (31 December 2025: HK\$5,685,000) of outstanding balance due to Shenzhen Zhongji Hirain Health Management Service Limited, being a related company as the chairman and executive director, Mr. Yan Li held 100% interest as at 30 June 2026.

Compensation of key management personnel

The remuneration of directors and other members of key management during the period is as follows:

	30 June 2026 HK\$'000 (Unaudited)	30 June 2025 HK\$'000 (Unaudited)
Salaries, allowances and benefits in kind	1,652	2,160
Pension scheme contribution	27	36
	<u>1,679</u>	<u>2,196</u>

MANAGEMENT DISCUSSION AND ANALYSIS

INTRODUCTION

Zhong Ji Longevity Science Group Limited (the “**Company**”), together with its subsidiaries (collectively the “**Group**”) have been focusing on expanding its longevity science business. In addition to operating and managing its existing businesses of money lending & financial advisory business, securities and other investment business, and property investment business. Since late 2022, the Company has been focusing on diversifying and has become Asia’s first one-stop health and longevity center, leading the way in human health and longevity.

Money Lending & financial advisory business

After emerged from the post-P2P loans transition phase during February 2022 restructure, the money lending and financial advisory business of the Company’s main subsidiary in the People’s Republic of China (“**PRC**”), 天行紀元(北京)財務顧問有限公司 (“**Tian Xing**”) of Beijing has restructured its operations, rehired new staff and disassociating from all former managerial staff, employees, and advisors involved. Tian Xing has successfully restored its business partnerships and banking authority operations by June 2023 thereafter. As announced, those Tian Xing mortgage loans were executed under strategic partners their license name, whereby Tian Xing takes a leading role responsible for works such as customer sourcing, data analysis, collateral valuation, credit assessment, and recovery of overdue payments and is exposed to the risk of bad debts. These strategic partners are not customers of the Company but those residential mortgage borrowers are the direct clients base of Tian Xing providing with broker, lending and collections services to them.

After undergone prolonged property slump during FY2023, FY2024 and FY2025 in recent years, leading to challenges in the residential property market in PRC. In particular, individuals and property investors have become more hesitant in purchasing property and property developers have become more cautious in tendering for residential developments. This leads to a continuous decrease in demand for residential mortgages and property secured corporate loans. Under such challenging market backdrop in PRC, during 2023 and 2024, policy changes by the PRC central government (“**國務院**”) enforced through the China Banking and Insurance Regulatory Commission (“**中國銀保監會**”) further delayed the recovery process, with decree policies included 銀保監辦發37號 (2022) issued on 6 April 2022, and 中國人民銀行中國銀行保險監督管理委員會銀發252號 (2022), have granted borrowers mortgage repayment relief. These decree policies offered at least six-month grace periods, waivers on overdue interest and recovery fees on grievance grounds, and other COVID-19-related relief measures. Consequently, these decree policies prolonged the recovery timeline and increased associated costs and uncertainties, making it more challenging for the Tian Xing and its Strategic Partners to execute mortgagee sales or other legal recovery actions.

During HY2026 the money lending and financial advisory business of Tian Xing and continued on a steady recovery path. The demand for secured home loans undergone trough and subdued property transactions across PRC regions, has now shown signs of recovery. This was largely driven by promising growth and developments on high-value new technology across multiple industries in PRC, inflation expectations induced by tariffs, and stable global economic growth forwards.

For Strategic Partners loan (FOTIC, ShanXi) under Arrangement 1 with Company supply 100% loan principal sum. To expedite this kind of hundred individual borrowers loan recovery process, in late April 2023, the Board engaged PRC law firm Dongwei 北京市東衛(南京)律師事務所 (“**Dongwei**”) with team of legal counsels across 23 Dongwei branches across PRC different cities working together with Company designated staffs, in execute legitimate recovery actions on overdue loans with “陝西省國際信託投資股份有限公司 Shanxi International Trust Co. Ltd” (“**ShanXi**”) and “中國對外經濟貿易信託有限公司 China Foreign Economy and Trade Trust Co., Ltd.” (“**FOTIC**”) Beijing City these Strategic Partners’ loans of considerable work sizes. On August 2024, this Dongwei service contract with TianXi and the Company was extended for further 36 months thereafter. The engagement with Dongwei was charge on a pro rata fees basis to successful recovery sum (in both monetary or property titles) with working expense disbursements, that save Company to incur significant on-going recovery staffs’ costs on few hundred debtors’ collection.

For Strategic partners loan (Haier, Fanhua) under Arrangement 2 with the Company only supply partial 20–30% initial loan principals, these overdue loans were with other Two Strategic Partners: “重慶輝科諾企業管理有限公司 via 重慶海爾小額貸款有限公司” (“**Haier**”); “深圳泛華聯合投資集團有限公司 Shenzhen Fanhua Joint Investment Group Co., Ltd.” (“**Fanhua**”); were all handled by the Company team alone with legal conveyance service undertake by individual law firms when required.

Longevity Science Business

For HY2026, continue undergone diagnostic consultation and medical testing segment service transformation, the Company will focus to acquisition means diversifying into promising longevity medical health businesses, offering a range of advanced medical services and health management so to enhance its financial performance.

The Company remained committed to establishing a world-leading longevity science transformation and application platform, striving to provide the most advanced, high-standard personalized longevity management services, with a focus on cancer prevention, anti-aging, and knee health.

Throughout HY2026, the Group continued to expand and diversify its longevity science business, focusing on anti-cancer, anti-aging and knee joint health-boosting products through membership programs and distribution channels. The PRC and Hong Kong operations generated approximately HK\$0.3 million from the provision of diagnostic, medical testing, and health auxiliary services, and HK\$60.4 million from sales of health and medical products.

FINANCIAL RESULTS

The Group was principally engaged in the longevity science business, money lending & financial advisory business, securities and other investments, and property investments. Given such restraint trading environment and sluggish sentiment in PRC property market, in mitigate the volatility risk, the Group took a rather prudent approach in operating the Money Lending business (via Strategic Partners loans origination solely) and the Group strives to venture into the field of longevity science in an exhaustive and diversified manner to improve its product chains, via membership and distribution channels. The Company focusing on developing and expanding its longevity science business, with a bright promising prospect and can develop into a large-scale, viable and sustainable business in the future.

During HY2026, the Group recorded a total revenue of HK\$71,526,000 (HY2025: HK\$47,973,000). The Group recorded a loss for the period of HK\$6,370,000 (HY2025: loss for the period HK\$12,922,000). The money lending and financial advisory business demonstrate a static revenue of HK\$10,861,000 and a segment profit of HK\$9,479,000 for HY2026. Nevertheless, the longevity science business contributed a segment revenue of HK\$60,665,000 and a segment loss of HK\$6,395,000 for HY2026.

As at 30 June 2026, the basic and diluted loss per share were HK\$1.02 cents (30 June 2025: basic and diluted loss per share were HK\$2.29 cents).

As at 30 June 2026, the Group's consolidated net assets was HK\$437,462,000 (31 December 2025: HK\$424,994,000).

BUSINESS REVIEW

Money Lending & Financial Advisory Business

During HY2026, a segmental revenue of approximately HK\$10,861,000 (HY2025: HK\$13,720,000) and a segmental profit of approximately HK\$9,479,000 (HY2025: HK\$12,306,000) were recorded. The stable segmental results was due to stable in interest receivables balances derived by the strategic partners loan portfolio (FOTIC, Fanhua, Haier, ShanXi) in the PRC stated in other receivables for HY2026.

Around September 2023 and June 2024, Dongwei with Company have managed to recover RMB6.7 million cash from two individual borrowers their arrear loans of ShanXi strategic partners and RMB2.9 million cash from ShanXi trustee account held for Tian Xing in final settlement, less ShanXi trustee service fees of RMB600,000 and an agent fee of RMB100,000 and initial setup legal fees RMB1,000,000. Hence by 30 June 2024, TianXing has now retrieve in full sum on invested principal RMB7,900,000 together with RMB1,700,000 returns less associated costs from the ShanXi strategic partner.

On record a typical individual borrower case in process by Dongwei now, shown take around 6 months or more for PRC Court of First instance (“CFI”) to obtain a satisfactory judgment and next at least 6 to 9 months in execute mortgagee sale or titles change pursuant to CFI judgement via PRC Execution Court. At late November 2024, Dongwei team of counsels were retrieve, compile and organize approximately 49 debtors’ cases materials to continue in pursuit on various Beijing, Tianjin and Wuxi courts on these FOTIC debts on behalf of Tian Xing subsidiary.

In the past period September and late November 2024, for Strategic partners loan under Arrangement 2 the Company team and directors have approached Fanhua and Haier management, with on-going negotiations onto monetarize the partial or whole loans portfolio with respective institutions Fanhua and Haier. If Tian Xing portion of the whole loans portfolio with Fanhua and/or Haier were monetarize by selling back to Fanhua and/or Haier or any designated institution, the Company pursuant to Chapter 14 shall made appropriate announcement on the details therein in forward periods.

During HY2026, pursuant to regulatory authority past guidance letters in recover of Hong Kong, Joy Wealth Finance Limited (“**Joy Wealth**”), a wholly-owned subsidiary of the Company, outlined 36 loans, being priorly impaired as, of aggregate outstanding amount approximately HK\$1,076,000,000 as at 31 December 2019 the authority has urged in pursuit. As announced in the announcement dated 11 August 2022, an Independent Recovery Committee (“**Independent Recovery Committee**”) was established to prepare, analysis, search information and materials before negotiate with borrowers to recover outstanding loan amounts and interest receivables assess the effectiveness of proceeding existing or potential legal procedures for taking over the ownership of pledged assets from the borrowers and guarantors.

Even though the outstanding loans were already impaired in FY2019, the Company has actively continued to follow up and hopes to recover such outstanding loans to the best of its ability. From August 2022 to 30 June 2026, this recovery exercise has completed to a stage of review assessment whereby Independent Recovery Committee has successfully recovered gross proceeds from two borrower entities of four loans out of these long impaired 36 loans occurred in Hong Kong, PRC, Saipan and British Virgin Islands, but this whole recovery exercise shall in continue. For HY2026, Joy Wealth did not derive any interest income (HY2025: nil) from these loan and interest receivables.

BUSINESS MODEL FOR MONEY LENDING & FINANCIAL ADVISORY BUSINESS AND LOAN PORTFOLIOS

The money lending and financial advisory business would operate in the following two models:

1. The “Strategic Partners Business Model” — offering related financial management and consulting service in the PRC via cooperation with PRC licensed strategic partners (without Company assuming role of a direct lender) with sizeable loans portfolio (including outstanding principals and interests) secured by residential assets. Such loan assets were accounted for as “Other receivables” under the category of “Deposits, Prepayments & Other receivables” set out in note 16 to the condensed consolidated financial statements.
2. The “Corporate and personal borrowers Business Model” — wherein the Company act as a direct lender and such loan assets (including outstanding principals and interests) were accounted for as “Loans and interest receivables” set out in note 14 to the condensed consolidated financial statements.

As at 30 June 2026, our Company had 398 (31 December 2025: 398) active accounts, of which 389 (31 December 2025: 389) of them were individual customers and the remaining of 9 (31 December 2025: 9) were corporate customers; and of which 375 (31 December 2025: 375) of them were under the strategic partners business model and 14 (31 December 2025: 14) of them were under the corporate and personal borrowers business model.

For HY2026, our top five customers (as determined by interest income generated) accounted for approximately 52% (HY2025: 51%) of our total revenue, and our single largest customer accounted for approximately 38% (HY2025: 30%) of our total revenue.

As at 30 June 2026, the largest and top five customers (as determined by loan receivable balance) of the total gross loan receivables balance accounted for 39% and 90% (31 December 2025: 39% and 90%) respectively.

(a) The Strategic Partners Business Model

The strategic partners under this model are PRC regulated trustee & fund manager companies of material sizes licensed in offering legitimate short to medium-term secured home loans (1st and 2nd mortgages) to individual borrowers across the regions of: Chongqing, Chengdu, Suzhou, Wuhan, few at Shanghai, Tianjin and Wuxi cities. All underlying mortgage borrowers and strategic partners personnel under this model are independent third party (within the meaning of Chapter of 14A of the Listing Rules), and were not connected persons or senior management of the Group.

Below are the current strategic partners in co-operation with the Company's wholly-owned Beijing subsidiary 天行紀元(北京)財務顧問有限公司 (“**Tian Xing**”) in PRC:

- (i) “中國對外經濟貿易信託有限公司 China Foreign Economy and Trade Trust Co., Ltd.” (“**FOTIC**”) a state-owned asset management company in the PRC operating at Beijing City; and
- (ii) “深圳泛華聯合投資集團有限公司 Shenzhen Fanhua Joint Investment Group Co., Ltd.” (“**Fanhua**”) a sizeable financial services company listed on the New York Stock Exchange (stock code: CNF); and
- (iii) “重慶輝科諾企業管理有限公司 via 重慶海爾小額貸款有限公司” (“**Haier**”) established since 2014 and owned by the electronic conglomerate Haier Group; and
- (iv) “陝西省國際信託投資股份有限公司 Shanxi International Trust Co. Ltd” (“**Shanxi**”) a state-owned trustee assets management company established since 1985 and listed on Shenzhen Stock Exchange (stock code: 00563).

Strategic Partners Corporation Agreements were performed in two kinds of arrangement:

Arrangement 1: strategic co-operation with FOTIC, Shanxi as outlined below:

The Company through its wholly-owned Beijing subsidiary Tian Xing invested monies into FOTIC, Shanxi, whereby these licensed strategic partners in PRC grant legitimate mortgage loans to borrowers. These mortgages typically run for a period of two to five years or longer on a pre-arranged return rate of 12% annually.

The Company would co-manage mortgages with FOTIC, Shanxi to monitor the risk profiles of individual borrowers, collaborate to pursue loan collection, assist FOTIC, Shanxi to take collateral enforcement actions, and provide management services including but not limited to client procurement, client's background check and credit rating due diligence. The Company would receive a management service fee from the mortgages and others assistance fees (if any) from individual borrower for the aforesaid services.

As at 30 June 2026, the Company receive those mortgages underlying loans accrued interests, after FOTIC Shanxi's expenses, pursuant to debts transfer contracts, but the underlying loans security were still registered under Strategic partners name per loan license regime of PRC. Hence any legal mortgagee recovery or security realization would still lodge together with strategic partners. Nevertheless, the Company takes over all benefits from the post-collection on all proceeds of mortgagee sale of any residual assets of mortgages registered in the Strategic Partners name (including but not limited to collection of any outstanding loans receivables).

Arrangement 2: The Strategic cooperation with Fanhua, Haier is summarized below:

The Company would procure potential borrowers and, after performing credit assessment, refer them to Fanhua, Haier. In return, the Company would receive loan origination fees/referral/agency fees from Fanhua, Haier or from individual borrowers depending on the amount of actual interest income received by Fanhua, Haier and the repayment status of the loans.

As a protection to Fanhua, Haier, the Company would be required to maintain a sum equivalent to 20–30% of the initial loan principals borrowed by customers referred to Fanhua, Haier as “a risk provision top-up fund”. Such sum in the risk provision fund will be used to settle the payment of principals and/or interests in the event of the borrower's default or in case of long-terms arrears. (During HY2026, the Company was disputing with Fanhua and/or Haier on implications PRC National Covid-19 mortgage reliefs Policy triggered some loans in technical defaults or arrear repayments in postpone).

The Company shall, following the liquidation of a particular borrower, take over the benefits from the post-liquidation of any residual assets in the loans (including but not limited to collection of any outstanding loans receivables and interest income, default interest and penalty fees). The Company may choose to acquire the entire defaulted loan principal balance from Fanhua, Haier their portions and seek recovery of the whole defaulted loans using its own means and resources.

Subject to terms and clauses of each strategic partners agreement, the Company earns: (1) loans origination fees; (2) management service fee rendered including services as client procurement, client's background check and credit rating due diligence; (3) recovery fees or penalty fees/interest for deferred loans; and (4) accrued interest income by providing whole/partial funding secured loans via strategic partner's license. The Company subsidiary attributes 10% loan principal sum of each small secure loans offer by two strategic partners of Fanhua and Haier, while such Strategic Partners would attribute the 90% remaining loan principal themselves; and the Company subsidiary attributes 100% loan principal sum of each home loans made under FOTIC.

Size and diversity of borrowers under the Strategic Partners Business Model

The strategic partners act as direct lender with the Company as co-manager over all mortgages.

In case of FOTIC and Shanxi, the average loans size (of 1st mortgage) was approximately RMB0.86 million. The loans were made within Beijing city or major cities. For HY2026, the interest rate chargeable by FOTIC and Shanxi Trust to borrowers ranged from 8.4% to 19.2% (HY2025: 8.4% to 19.2%).

In the case of other strategic partners, Fanhua & Haier, their average loans size (of 1st and 2nd mortgage) was approximately RMB0.2 million. The loans were made across Chongqing, Chengdu, Suzhou, Wuhan cities with few in Shanghai, Tianjin, and Wuxi cities. For HY2026, the interest rate chargeable by Fanhua & Haier to borrowers ranged from 12% to 18% (HY2025: 12% to 18%).

Five largest borrowers under Strategic Partners Business Model	Loan principal amount as at 30 June 2026 <i>RMB'000</i>	Concentration ratio of other receivables	Secured Collateral Loan Leverage ratio
Borrower A (via FOTIC)*	5,000	3.868%	48.08%
Borrower B (via FOTIC)*	4,500	3.481%	52.96%
Borrower C (via FOTIC)*	4,250	3.288%	26.74%
Borrower D (via FOTIC)*	4,200	3.249%	29.25%
Borrower E (via FOTIC)*	4,000	3.094%	54.05%
		<u>16.98%</u>	

Note:* In accumulated, the Group had 3,597 (HY2025: 3,597) individual borrowers on secure loans of collaterals (residential house) via the Strategic Partners Model (FOTIC, Shanxi, Fanhua and Haier) act as Lender.

As at 30 June 2026, strategic partners loan assets were accounted as other receivables for approximately HK\$194,596,000 before impairments (31 December 2025: HK\$184,634,000 with net carrying value approximately HK\$151,851,000 (31 December 2025: HK\$141,888,000)). The top five loans borrower under Strategic Partners Business Model was accounted for approximately total 16.98% of the entire other receivables of the Group as at 30 June 2026 (31 December 2025: 17.272%), and their collaterals value leverage ratio range from 26.74% to 54.05% secured on properties.

(b) The Corporate and personal borrowers Business Model

The Company's corporate and personal borrowers loan business comprises of loans made to corporate entity and/or wealth personal borrowers via the Company wholly owned subsidiary in PRC and/or Hong Kong acting as a direct lender via loan agreements with security mostly, except few loans in past on were trade credits or unsecured or intangible security basis alike dividends rights. All underlying borrowers under this model are independent third party (within the meaning of Chapter of 14A of the Listing Rules), and were not connected persons or senior management of the Group.

Size and diversity of borrowers under the Corporate and personal borrowers Business Model

The Company acts as direct lender and manages these over 14 corporate and personal borrowers loans, despite some of the loans have been already impaired before the year of 2022. The loans principal size ranges from approximately HK\$47.9 million for personal borrower to a corporate loan principal size of approximately HK\$64.4 million, with interest rates ranged from 6% to 18%, mostly with security, but some are unsecured or secured with certain company dividend or secure intangible assets. These loans were accounted for as Loans and interest receivables set out in note 14 to the consolidated financial statements.

Five largest borrowers under Corporate and personal borrowers Business Model	Loan principal amount as at 30 June 2026		Concentration ratio of loan and interest receivables	Secured Collateral Loan Leverage ratio
	RMB'000	HK\$'000		
Borrower A	—	298,000	34.58%	Unsecured
Borrower B	—	163,003	18.53%	Unsecured
Borrower C	128,000	—	17.14%	100%
Borrower D	—	35,000	4.06%	Unsecured
Borrower E	24,500	—	3.28%	Unsecured
			<u>77.59%</u>	

As at 30 June 2026, the corporate and personal borrowers business loan assets were accounted as loan and interest receivables for approximately HK\$861,564,000 before impairments (31 December 2025: HK\$844,484,000), with net carrying value approximately HK\$186,401,000 (31 December 2025: HK\$169,324,000). The top five loans borrower under Corporate and Personal borrowers Business Model was accounted for approximately total 84.08% of the entire loan and interest receivables of the Group as at 30 June 2026 (31 December 2025: 92.33%), and their collaterals

value leverage ratio range from 31.79% to 74.69% secured on properties, financial assets and dividend rights or unsecured. These loans were made in prior years on exiting P2P old business and subsequently impaired in later prior years. Nevertheless, the Company has recently initiated recovery actions on these previously partially or wholly impaired loans as above mentioned.

Longevity Science Business

The Group recognizes the strong growth potential of the longevity science segment. Focusing on its main business “longevity biological products and longevity management”, the company continues to improve work efficiency and quality while strengthening and improving the industrial chain and product chain. Indeed, the COVID-19 and the aging population have aroused public high concern for health across the globe, resulting in unprecedented potentials for the development of Longevity products and testing services in the healthcare and medical industry.

During this reporting period, the Group’s longevity science business delivered undesirable performance due to certain one-off costs, unforeseeable events on nicotinamide mononucleotide (“NMN”) products status change, difficult ex-post pandemic operation environment. The revenue of this segment amounted to approximately HK\$60,665,000 for HY2026 (HY2025: HK\$34,253,000), of which, approximately HK\$287,000 was generated from diagnostic consultation and medical testing, and approximately HK\$60,378,000 was contributed by the sales of longevity biological products.

The Group recorded a segmental loss for longevity science business of approximately HK\$6,395,000 for HY2026 (HY2025: loss HK\$10,495,000), was mainly due to:

- i. Shenzhen Longevity Science subsidiary has undergone material restructuring costs incurred associated total revamp on the whole marketing channel for diagnostic consultation and medical testing to change from individual sale staff to contractual referrals arrangement with channel parties alike Banks, Insurance Companies and Wealth management entities. Hence these (diagnostic consultation and medical testing) service income was hampered in this period; and
- ii. The Board in FY2024 later months has incurred initial setup costs to develop this “American Wild Ginseng Wine 野生西洋參酒” health biological products trade to enhance Company existing health and supplement products sale, which show good promising sale records within preliminary stage months.

Despite recorded losses by Shenzhen Longevity Science subsidiary within reporting period, the management of the Group is optimistic on the development of the longevity science business, and believes that the longevity science business will be the driver of the Group’s revenue growth in the future, together with existing license money lending business steady growth.

Securities and Other Investment Business

As of 30 June 2026, the Group did not hold any long-term investments in equity securities listed on the Stock Exchange (as of 31 December 2025: HK\$Nil).

Property Investment Business

During the years ended 31 December 2023 and 2022, the Company discovered that the leasehold interest of the property in Saipan has been unlawful and unauthorized transferred pursuant to a lease agreement without any knowledge and any lawful authority of Zhong Ji., which originally was held by Keen State Global (CNMI) LLC (“**Keen State Global Saipan**”), an indirect wholly own subsidiary of the Group.

During the year ended 31 December 2023, the Company therefore authorized a Saipan law firm (“**Saipan Legal Advisor**”) to commence legal actions in order to invalidate the forged lease assignment, recover the possession of leasehold interest, trace the consideration provided by the assignees under the lease agreement, rectify the record and report the case to the Police of Saipan and other appropriate authorities on behalf of Zhong Ji.

The legal recovery has achieved stage conclusion from Superior Court for the Commonwealth of the Northern Mariana Islands (“**Superior Court**”) made a Final Order on 7 July 2025 that the defendant’s Motion to Dismiss was denied (claimant application to recovery has sustained), and parties shall appear for a status conference on 20 October 2025 for court discussion and handling on the restoration of this Saipan leasehold interest registration issue.

On 20 October 2025 this Superior Court case management hearing (status conference), legal representative of only one defendant has appeared with the second defendant and its legal representative absence with reason, held to manage the upcoming settlement on the claimant recovery on the leasehold interest and/or monetary compensations. The Superior Court has ordered a settlement hearing on 7 December 2026 thereafter.

As advised, the Company director has instructed the Saipan Legal Advisor seek from the Superior Court to expedite this settlement hearing on a earlier date.

As at 30 June 2026 and date of this announcement, in view of the directors of the Company, the Group has the ownership of the investment properties of Saipan and the Group’s possession of investment properties was still valid. The Company will continue to actively engage with the Saipan Legal Advisor to address these matters and will provide timely disclosures regarding any developments.

FINANCIAL REVIEW

Liquidity and Financial Resources

During HY2026, the Group's operation and capital requirements were financed principally through share capital, retained earnings and bank and other borrowings. As at 30 June 2026, the Group had recorded net current assets of approximately HK\$412,611,000 (31 December 2025: HK\$399,313,000); and cash and bank balances of approximately HK\$13,400,000 (31 December 2025: HK\$24,299,000). Cash and cash equivalents as at 30 June 2026 were all denominated in Hong Kong dollars. The Group did not enter into any financial instruments for hedging purpose.

As at 30 June 2026, the Group had bank and other borrowing of HK\$2,238,000 (as at 31 December 2025: HKNil). Details of bank and other borrowing are set out in note 19 to the condensed consolidated financial statements.

Capital Structure

As at 30 June 2026, the total number of the issued ordinary shares with the par value of HK\$0.01 each was 636,654,300 (31 December 2025: 636,654,300).

Significant Investment Held, Material Acquisition or Disposal of Subsidiaries and Affiliated Companies and Plans for Material Investment or Capital Assets

There was no significant investment held, material acquisition or disposal of subsidiaries and affiliated companies during HY2026.

Securities in Issue

As at 30 June 2026, there were 636,654,300 ordinary shares in issue.

Segment Information

Details of segment information of the Group for HY2026 are set out in note 4 to the condensed consolidated financial statements.

Employees and Remuneration Policy

As at 30 June 2026, the Group had approximately 31 employees (31 December 2025: 43). The employee benefits expense, excluding Directors' emoluments, of the Group were approximately HK\$8.6 million (HY2025: \$8.2 million) in HY2026 and increased by approximately 4.8% compared to HY2025. The employees of the Group were mainly stationed in Hong Kong and the PRC. In-house training programs were provided for its employees to enhance their skills and job knowledge. The management of the Company would continue to foster close cooperation among the employees.

The Group regularly reviews and determines the remuneration and compensation package of the Directors and the Senior Management with reference to, among other things, the market level of salaries paid by comparable companies, the respective responsibilities of the Directors and the Senior Management and the performance of the Group. In order to attract and retain high quality staff, competitive remuneration package is offered to employees (with reference to market norms and individual employees' performance, qualification and experience). On top of basic salaries, bonuses may be paid with reference to the Group's performance as well as individual employees' performance. In addition, training and development programmes are provided on an on-going basis throughout the Group. The remuneration policy of the Group was reviewed regularly, making reference to current legislation, market condition and both the performance of individual employees and the Group.

In order to align the interests of staff with those of shareholders of the Company, share options were granted to relevant grantees, including employees of the Group, under the Company's share option scheme adopted on 29 July 2022. Share options carrying rights to subscribe for a total number of 3,868,000 shares (as adjusted taking into account the effect of the Share Consolidation) of the Company remained outstanding as at 30 June 2026. A share award scheme (the "**Share Award Scheme**") was also adopted by the Company on 18 May 2021. The Company may from time to time, allot and issue new shares in the share capital of the Company to the trustee as directed by the Board and/or share award committee, which shall constitute part of the trust fund, for the grant of restricted shares to selected participant(s) as set out in the rules of the Share Award Scheme and the trust deed. No Restricted Shares have been granted under the Share Award Scheme up to the date of this report and thus no shares in the Company would be issued accordingly. No shares were awarded under the Share Award Scheme of the Company during HY2026 and HY2025. The Award Scheme expired on 18 May 2031.

Details of Charges on Assets

As at 30 June 2026, the Group did not pledge any assets to banks or other financial institutions nor did the Group have any corporate guarantee given to any entity (31 December 2025: Nil).

Treasury Policy

The Group has adopted a treasury policy on 24 May 2011 in relation to the Group's investment in securities of other listed companies on the Stock Exchange. The objective of the policy is to enable the Group to control and govern the possible future securities investments (if any, which may or may not occur).

Gearing Ratio

The gearing ratio of the Group as at 30 June 2026 (defined as the Group's total interest-bearing liabilities divided by the Group's total equity) was approximately 0.5% (31 December 2025: 0%).

Foreign Exchange Exposures

Business transactions of the Group are mainly denominated in Hong Kong dollars and Renminbi. The Group has not implemented any foreign currency hedging policy at the moment. However, in view of the fluctuation of Renminbi in recent years, continuous monitoring on the foreign exchange exposure is carried out and the management will consider hedging the foreign exchange exposure if it has material impact on the Group.

Capital Commitment

As at 30 June 2026, the Group did not have any capital commitment (31 December 2025: Nil).

Contingent Liability

As at 30 June 2026, the Group had no material contingent liability (31 December 2025: Nil).

EVENTS AFTER THE REPORTING PERIOD

1. On 7 July 2026, the Company announced that Shenzhen Zhong Ji Health Science Co., Ltd.* (深圳市中基健康科學有限公司) (“**Zhong Ji Health**”), a wholly-owned subsidiary of the Company, entered into a memorandum of cooperation Shenzhen Zhongtong Huijin Fund Management Co., Ltd.* (深圳中投匯金基金管理有限公司) (“**Shenzhen Zhongtong**”).

Further details are disclosed in the announcement of the Company dated 7 July 2026.

2. Reference is made to the announcements of the Company dated 1 December 2025 (the “**1st Announcement**”) and dated 2 April 2026 (the “**2nd Announcement**”). Unless otherwise defined herein, capitalized terms used herein shall have the same meanings as defined in the 1st Announcement and the 2nd Announcement.

Under the Sale and Purchase Agreement, the Vendor and the Guarantor jointly and severally and irrevocably and unconditionally, undertake that subject to Completion, the audited net profits before taxation of the Target Company (excluding any extraordinary items) under the Hong Kong Financial Reporting Standards and Hong Kong Accounting Standard in respect of:

- (a) the 12 months period from 1 January 2025 to 31 December 2025 shall not be less than HK\$50,000,000; and
- (b) the 12 months period from 1 January 2026 to 31 December 2026 shall not be less than HK\$50,000,000.

Further details are disclosed in the announcement of the Company dated 21 August 2026.

CORPORATE GOVERNANCE

The Company has complied with the code provisions (the “**Code Provision(s)**”) set out in the Corporate Governance Code (the “**CG Code**”) contained in Appendix C1 to the Listing Rules during HY2026.

DIRECTORS’ SECURITIES TRANSACTIONS

The Company has adopted the code of conduct regarding directors’ securities transactions as set out in the Model Code for Securities Transactions by Directors of Listed Issuers (the “**Model Code**”) in Appendix C3 of the Listing Rules. Having made enquiry to all Directors, they all have confirmed that they have complied with the required standards as set out in the Model Code during the year.

The Company has adopted the terms contained in the Model Code for Security Transactions by Directors of Listed Issuers as set out in Appendix C3 of the Listing Rules as the Company’s code of conduct for security transactions and dealing (the “**Model Code**”). All existing Directors, upon specific enquiry, have confirmed that they have complied with the Model Code during HY2026.

PURCHASE, SALE OR REDEMPTION OF SHARES

During HY2026, neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company’s listed shares.

INTERIM DIVIDEND

The Directors did not recommend the payment of any interim dividend for HY2026 (HY2025: Nil).

AUDIT COMMITTEE REVIEW

As at the date of this announcement, the Audit Committee comprises four members comprising all the independent non-executive Directors, namely, Mr. Huang Jiang (who acts as the chairman of the Audit Committee), Ms. Wang Huijuan, Ms. Tam Mei Chu and Prof. Huang Cibo.

The primary duties of the Audit Committee are to assist the Board by providing an independent view of the effectiveness of the financial reporting process, internal control and risk management system of the Group, to oversee the audit process, to develop and review the Group’s policies and to perform other duties and responsibilities as assigned by our Board. The Audit Committee discussed the accounting principles and policies adopted by the Group together with the management.

The condensed consolidated financial statements of the Group of interim results for HY2026 have been reviewed and approved by the Audit Committee, and the Audit Committee is of the opinion that such financial statements comply with the applicable accounting standards, the Listing Rules and all other applicable legal requirements. The Audit Committee therefore recommended the Board's approval of the Group's consolidated financial statements for HY2026.

PUBLICATION OF INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

This interim results announcement is published on both the website of the Stock Exchange (<https://www.hkexnews.hk>) and the Company (<https://www.irasia.com/listco/hk/zhongjilongevity>). The interim report of the Company for HY2026 containing all information required by the Listing Rules will be despatched to the Shareholders and will be published on the respective websites of the Stock Exchange and the Company in due course.

As at the date of this announcement, the Directors are:

Executive Directors

Mr. Yan Li (*Chairman*)
Mr. Li Xiaoshuang

Non-executive Directors

Dr. He Yiwu
Mr. Lyu Changsheng

Independent Non-executive Directors

Mr. Huang Jiang
Prof. Huang Cibo
Ms. Wang Huijuan
Ms. Tam Mei Chu

By order of the Board

Zhong Ji Longevity Science Group Limited

Yan Li

Chairman, Chief Executive Officer and Executive Director

Hong Kong, 27 August 2026

In case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.